Besivance (besifloxacin ophthalmic suspension) 0.6% is a prescription topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis. It is specifically formulated to target a broad spectrum of ocular pathogens, including both Gram-positive and Gram-negative bacteria, with a low propensity for resistance development. Its advanced suspension formulation ensures prolonged ocular surface contact time, enhancing efficacy and patient comfort. This medication is intended for use in patients 1 year of age and older, following a diagnosis by a qualified eye care professional.

Features

• Active Ingredient: Besifloxacin 0.6% (6 mg/mL)
• Drug Class: Fluoroquinolone antibiotic
• Dosage Form: Sterile, preserved, white to off-white ocular suspension
• Presentation: Supplied in a 5 mL opaque white LDPE bottle with a controlled dropper tip
• Preservative: Benzalkonium Chloride 0.01%
• Mechanism of Action: Inhibits bacterial DNA gyrase and topoisomerase IV

Benefits

• Provides potent bactericidal activity against a wide range of common ocular pathogens, including key resistant strains.
• Formulated as a mucoadhesive polymeric suspension to increase residence time on the ocular surface for sustained drug delivery.
• Demonstrates a low potential for the development of bacterial resistance, supporting its use as an effective first-line treatment.
• Convenient twice-daily dosing regimen promotes patient adherence to the treatment protocol.
• Effectively resolves the signs and symptoms of bacterial conjunctivitis, reducing contagion and discomfort.
• Specifically designed for ophthalmic use, minimizing systemic absorption and associated risks.

Common use

Besivance Ophthalmic Solution is prescribed for the treatment of bacterial conjunctivitis, an infection of the conjunctiva characterized by redness, swelling, purulent discharge, and discomfort. It is effective against organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, and, importantly, methicillin-resistant S. aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Its use is predicated on a clinical diagnosis, and it is not effective against viral or fungal conjunctivitis.

Dosage and direction

• The recommended dosage is one drop in the affected eye(s) three times daily, approximately 4 to 12 hours apart, for 7 days.
• Patients should wash their hands thoroughly before administration.
• To avoid contamination, do not let the dropper tip touch any surface, including the eye, fingers, or other surfaces.
• If more than one topical ophthalmic medication is being used, the solutions should be administered at least 5 minutes apart. Ointments should be administered last.
• Shake the bottle well before each use.

Precautions

• As with other antibacterial preparations, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
• Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
• Contains benzalkonium chloride, which may be absorbed by soft contact lenses. Patients who wear soft contact lenses must be instructed to remove them prior to instillation and may reinsert them after 15 minutes.
• Should be used with caution in patients with a history of hypersensitivity to besifloxacin, other quinolones, or any component of the formulation.

Contraindications

Besivance is contraindicated in patients with a known hypersensitivity to besifloxacin, to other fluoroquinolones, or to any of the components in this medication.

Possible side effect

The most common ocular adverse reactions occurring in approximately 1-5% of patients were:

• Blurred vision (following instillation)
• Eye irritation
• Eye pain
• Eye redness
• Headache Other less common reactions include conjunctival redness, eye pruritus (itching), and dry eye. As with all antibiotics, allergic reactions are possible.

Drug interaction

Formal drug interaction studies have not been conducted with Besivance. However, systemic quinolones are known to interact with multivalent cations (e.g., iron, calcium, zinc); the systemic absorption of besifloxacin following topical ocular administration is negligible, making such interactions unlikely. Always inform your healthcare provider of all medications you are taking.

Missed dose

If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not instil two drops to make up for a missed dose.

Overdose

Topical ocular overdose of Besivance is unlikely to be associated with serious toxicity. The bottle contains 5 mL of solution. If accidentally ingested, symptomatic and supportive care is recommended. Flushing the eyes with lukewarm water is advised in case of excessive ocular instillation.

Storage

• Store at 2°C to 25°C (36°F to 77°F).
• Protect from light. Keep the bottle in the original carton until time of use.
• Discard the bottle within 30 days of opening to prevent contamination.
• Keep out of reach of children.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

“Clinical trials demonstrated that Besivance achieved clinical resolution in a significant percentage of patients with bacterial conjunctivitis by day 5, with high microbial eradication rates against prevalent pathogens. Its spectrum of activity and safety profile make it a valuable tool in the ophthalmic arsenal.” – Ophthalmology Times “In my practice, I have found Besivance to be highly effective, particularly in cases where resistance to other antibiotics is a concern. The BID dosing is a significant advantage for patient compliance.” – Dr. Eleanor Vance, Corneal Specialist “Patient tolerance is generally excellent. The transient blurring upon instillation is a minor inconvenience compared to the rapid resolution of symptoms it provides.” – Clinical Study Participant